EP4724584A2 - Particules pseudovirales contenant des systèmes d'expression d'arnm circulaire et leurs méthodes d'utilisation - Google Patents

Particules pseudovirales contenant des systèmes d'expression d'arnm circulaire et leurs méthodes d'utilisation

Info

Publication number
EP4724584A2
EP4724584A2 EP24820191.5A EP24820191A EP4724584A2 EP 4724584 A2 EP4724584 A2 EP 4724584A2 EP 24820191 A EP24820191 A EP 24820191A EP 4724584 A2 EP4724584 A2 EP 4724584A2
Authority
EP
European Patent Office
Prior art keywords
protein
virus
vlp
ires
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24820191.5A
Other languages
German (de)
English (en)
Inventor
Samie R. Jaffrey
Mildred UNTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of EP4724584A2 publication Critical patent/EP4724584A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une particule pseudovirale (VLP). La particule pseudovirale contient une molécule d'ARN circulaire comprenant : une première séquence de ligature ; un site d'entrée ribosomique interne (IRES) couplé à une molécule d'ARN codant pour un ou plusieurs peptides, le site d'entrée ribosomique interne couplé à la molécule d'ARN codant pour un ou plusieurs peptides étant positionné en 3' par rapport à la première séquence de ligature ; une seconde séquence de ligature positionnée en 3' du site d'entrée ribosomique interne couplé à la molécule d'ARN codant pour lesdits un ou plusieurs peptides ; et une pluralité d'une ou plusieurs protéines qui peuvent s'auto-assembler en une nanoparticule. Sont également divulguées des compositions et des méthodes de productions et d'utilisation de telles particules pseudovirales.
EP24820191.5A 2023-06-08 2024-06-07 Particules pseudovirales contenant des systèmes d'expression d'arnm circulaire et leurs méthodes d'utilisation Pending EP4724584A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506997P 2023-06-08 2023-06-08
PCT/US2024/033132 WO2024254546A2 (fr) 2023-06-08 2024-06-07 Particules pseudovirales contenant des systèmes d'expression d'arnm circulaire et leurs méthodes d'utilisation

Publications (1)

Publication Number Publication Date
EP4724584A2 true EP4724584A2 (fr) 2026-04-15

Family

ID=93796442

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24820191.5A Pending EP4724584A2 (fr) 2023-06-08 2024-06-07 Particules pseudovirales contenant des systèmes d'expression d'arnm circulaire et leurs méthodes d'utilisation

Country Status (2)

Country Link
EP (1) EP4724584A2 (fr)
WO (1) WO2024254546A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237372A1 (fr) * 2017-06-23 2018-12-27 Cornell University Molécules d'arn, procédés de production d'arn circulaire, et procédés de traitement
KR20210018323A (ko) * 2018-06-06 2021-02-17 매사추세츠 인스티튜트 오브 테크놀로지 진핵 세포에서의 번역을 위한 원형 rna
KR20230028375A (ko) * 2020-06-25 2023-02-28 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 원형 rna 번역을 구동하는 유전 요소와 이를 사용하는 방법
EP4392560B1 (fr) * 2021-08-27 2026-03-11 Peking University Constructions et procédés de préparation d'arn circulaire

Also Published As

Publication number Publication date
WO2024254546A2 (fr) 2024-12-12
WO2024254546A3 (fr) 2025-02-13

Similar Documents

Publication Publication Date Title
JP2024503698A (ja) 変異型株ベースのコロナウイルスワクチン
EP2333091B1 (fr) Vecteurs et méthodes pour immunisation génétique
EP4284931A1 (fr) Compositions et procédés d'administration de cargo à une cellule cible
TW202320864A (zh) 經工程改造之ｃａｓｘ抑制子系統
AU2019261438B2 (en) Expression of FOXP3 in edited CD34+ cells
EP4392560B1 (fr) Constructions et procédés de préparation d'arn circulaire
AU2021264061A1 (en) Engineered central nervous system compositions
KR20210113260A (ko) 캡슐화된 rna 폴리뉴클레오타이드 및 사용 방법
US20250002541A1 (en) Engineered central nervous system compositions
CN115666722A (zh) 包封的rna复制子和使用方法
TW202411426A (zh) 經工程化的２類ｖ型ｃｒｉｓｐｒ系統
KR20230044420A (ko) 바이러스 푸소좀을 생산하기 위한 방법 및 조성물
US20230340527A1 (en) Baculovirus expression systems
WO2023158487A1 (fr) Protéines de fusion à membrane spécifique de type cellulaire
US20250073350A1 (en) Compositions and methods for delivering cargo to a target cell
US20250064976A1 (en) Engineered pnma proteins and delivery systems thereof
CN118679248A (zh) 环状dna载体的合成产生
US20230227849A1 (en) Methods of identifying and characterizing anelloviruses and uses thereof
JP2025524620A (ja) 暗号化ｒｎａ及びその使用方法
CN114668837A (zh) 一种基于mRNA的新冠病毒野生型和变异型联合疫苗及其制备方法
TW202223095A (zh) 串聯指環病毒構築體
CN107847610A (zh) 基于piv5的扩增病毒样颗粒
WO2024254546A2 (fr) Particules pseudovirales contenant des systèmes d'expression d'arnm circulaire et leurs méthodes d'utilisation
CN121079404A (zh) 用于基因组编辑的组合物和方法
US20240366750A1 (en) Viral antigen display compositions and methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260106

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR